Tivozanib Monotherapy in the Frontline Setting for Patients with Metastatic Renal Cell Carcinoma and Favorable Prognosis

In this review, we discuss which patients with metastatic clear cell renal cell carcinoma (mRCC) may be most suitable for frontline tyrosine kinase inhibitor (TKI) monotherapy, a treatment option supported by emerging long-term efficacy data including overall survival and quality of life. We specifically focus on tivozanib, a potent and selective inhibitor of vascular endothelial growth factor receptor, which has comparable efficacy to other single-agent TKIs in frontline treatment for mRCC while exhibiting fewer off-target side effects.

Tivozanib Monotherapy in the Frontline Setting for Patients with Metastatic Renal Cell Carcinoma and Favorable Prognosis - Beyond the Abstract

Ricky Frazer MBBCH (Hons), MSc (MedEduc), BSc, PgCert (Onc), PgCert (ClinLead), PgCert (AcuteMed), MAcadMEd, MRCP, AFFMLM, Medical Oncology Consultant, Velindre Cancer Centre (VCC), Cardiff, Wales

Read the Abstract

Tivozanib Monotherapy in the Frontline Setting for Patients with Metastatic Renal Cell Carcinoma and Favorable Prognosis - Beyond the Abstract

Login